Impact of malignancy on In-hospital mortality, stratified by the cause of admission: An analysis of 67 million patients from the National Inpatient Sample.


Journal

International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 02 07 2021
accepted: 26 08 2021
pubmed: 8 9 2021
medline: 7 4 2022
entrez: 7 9 2021
Statut: ppublish

Résumé

To describe the patient characteristics and the reason for admission of patients with malignancy by malignancy, and to study mortality rates for the different causes of admissions among the different types of cancer. Using the nationwide Inpatient Sampling (2015-2017) we examined the cause of admission and associated in-hospital mortality, stratified by presence and type of malignancy. Multivariable logistic regression models were used to examine the association between in-hospital mortality and malignancy sites for different primary admission causes. Out of 67 819 693 inpatient admissions, 8.8% had malignancy. Amongst those with malignancy, haematological malignancy was the most common (20.2%). The most common cause of admission amongst all cancers were malignancy-related admissions, where up to 57% of all colorectal admissions were malignancy-related. The most common non-malignancy cause of admission was infectious causes, which were most frequent among patients with haematological malignancy (18.4%). Patients with malignancy had higher crude mortality rates (5.7% vs 1.9%). Mortality rates were highest among patients with lung cancer (8.7%). Among all admissions, the adjusted rates of mortality were higher for patients with lung (OR 3.65, 95% CI [3.59-3.71]), breast (OR 2.06, 95% CI [1.99-2.13]), haematological (OR 1.79, 95% CI [1.76-1.82]) and colorectal (OR 1.71, 95% CI [1.66-1.76]) malignancies compared with patients with no malignancy. Our work highlights the need to consider the burden of cancer on our hospital services and consider how the prognostic impact of different types of admissions may relate to the type of cancer diagnosis and understand whether these differences relate to disparities in clinical care/treatments.

Identifiants

pubmed: 34490963
doi: 10.1111/ijcp.14758
pmc: PMC8983059
mid: NIHMS1793364
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14758

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001438
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001436
Pays : United States

Informations de copyright

© 2021 John Wiley & Sons Ltd.

Références

Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
Cancer Med. 2020 Mar;9(5):1741-1752
pubmed: 31960609
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Crit Care. 2009;13(1):R15
pubmed: 19200368
NCHS Data Brief. 2016 Aug;(254):1-8
pubmed: 27598767
Eur Heart J. 2020 Jun 14;41(23):2183-2193
pubmed: 31800032
Am J Emerg Med. 2018 Nov;36(11):2038-2043
pubmed: 29573899
J Oncol Pract. 2018 Mar;14(3):e176-e185
pubmed: 29452549
Eur Heart J Acute Cardiovasc Care. 2021 Oct 27;10(8):829-839
pubmed: 33587752
Int J Clin Pract. 2020 May;74(5):e13476
pubmed: 31922635
Int J Clin Pract. 2021 Apr;75(4):e13798
pubmed: 33474781
JAMA Oncol. 2017 Oct 12;3(10):e172450
pubmed: 28859189
World J Emerg Med. 2014;5(2):85-90
pubmed: 25215154
JAMA Netw Open. 2019 Mar 1;2(3):e190979
pubmed: 30901049
Europace. 2020 Jul 1;22(7):1083-1096
pubmed: 32361739
Circ J. 2020 Sep 25;84(10):1771-1778
pubmed: 32921679
J Med. 1975;6(1):61-4
pubmed: 1056415
Crit Care Med. 2019 Oct;47(10):1310-1316
pubmed: 31356477
PLoS One. 2015 Mar 26;10(3):e0120827
pubmed: 25812117
Ann Surg. 2015 Apr;261(4):632-6
pubmed: 24743604
Asian Pac J Cancer Prev. 2010;11(6):1755-9
pubmed: 21338228
J Hematol Oncol. 2019 Sep 12;12(1):96
pubmed: 31511035
J Clin Oncol. 2012 Oct 20;30(30):3657-64
pubmed: 23008297
Ann Surg Oncol. 2010 Jul;17(7):1802-7
pubmed: 20155401
Lancet. 2019 Sep 21;394(10203):1041-1054
pubmed: 31443926
Pulmonology. 2020 May - Jun;26(3):123-129
pubmed: 31787563
Arch Surg. 2003 Jul;138(7):721-5; discussion 726
pubmed: 12860752

Auteurs

Ofer Kobo (O)

Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.
Keele Cardiovascular Research Group, Keele University, Stoke on Trent, United Kingdom.

Sherry-Ann Brown (SA)

Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Tarek Nafee (T)

Department of Medicine, Roger Williams Medical Center, Boston University School of Medicine, Boston, MA, USA.

Mohamed O Mohamed (MO)

Keele Cardiovascular Research Group, Keele University, Stoke on Trent, United Kingdom.

Kamal Sharma (K)

U.N. Mehta ICRC, B. J. Medical College, Ahmedabad, India.

Sedralmontaha Istanbuly (S)

Faculty of Medicine, University of Aleppo, Aleppo, Syrian Arab Republic.

Ariel Roguin (A)

Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.
Keele Cardiovascular Research Group, Keele University, Stoke on Trent, United Kingdom.

Richard K Cheng (RK)

Division of Cardiology, University of Washington Heart Institute, Seattle, WA, USA.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Keele University, Stoke on Trent, United Kingdom.
Institute of Population Health, University of Manchester, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH